Plain-English translation of NCT04745143 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Schizophrenia research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a medication called (an NMDA enhancer) as a standalone treatment for schizophrenia. The study focuses specifically on people who have not benefited from or cannot tolerate standard antipsychotic medications. Researchers believe this medication may help with both the core symptoms of schizophrenia and cognitive problems (like memory and thinking difficulties) that are especially hard to treat with current drugs.
Many people with schizophrenia either don't respond well to standard antipsychotics or experience severe side effects that make it impossible to stay on them. This medication represents a different approach that early research suggests might reduce symptoms while also protecting the brain from damage and improving thinking and memory—areas where current treatments fall short.
You likely qualify if…
You likely don't qualify if…
You would participate in a 6-week study where you take either the new medication or a placebo (inactive pill) by mouth. You'll visit the clinic every two weeks so researchers can check how you're doing, measure any side effects, and assess your symptoms. At the beginning and end of the study, you'll complete a set of cognitive tests to see if the medication helps with thinking and memory. The researchers will compare how well the medication works compared to placebo.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
Taiwan